ASBMR: Bisphosphonate Damage May Peak in First Year
Animal study suggests that skeletal microcracks do not accumulate with time
FRIDAY, Sept. 22 (HealthDay News) -- Most skeletal microdamage from bisphosphonate intake may max out in the first 12 months of treatment and may not accumulate over longer dosing, according to the results of an animal study presented at the 28th annual meeting of the American Society for Bone and Mineral Research.
Matt Allen, Ph.D., and David Burr, Ph.D., of the Indiana University School of Medicine in Indianapolis, evaluated alendronate dosing in one-year-old female beagles. The dogs were given oral alendronate at levels comparable to human doses or at levels fivefold higher than the clinical dose for one or three years.
Continued use of alendronate was not linked to progressive adverse effects on bone structure and strength. There was no increase in vertebral microcracks in dogs treated for three years with alendronate treatment compared to those treated for one year.
"Based on these results, we conclude that despite continued suppression of turnover and increases in bone density, microdamage does not continue to accumulate in alendronate-treated animals. This suggests microdamage accumulation is self-limiting with maximum accrual during the first year of treatment," the researchers reported.